Portal de Periódicos da CAPES

Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial.

1993; BMJ; Volume: 34; Issue: 2 Suppl Linguagem: Inglês

10.1136/gut.34.2_suppl.s144

1468-3288

Claudio Ferri, E Marzo, G. Longombardo, L La Civita, Fabrizio Lombardini, Dilia Giuggioli, Renato Vanacore, A. M. Liberati, Alessandro Mazzoni, Francesco Greco,

Hepatitis B Virus Studies

To confirm the positive results of a preliminary trial, 26 patients with mixed cryoglobulinaemia were enrolled in a controlled, randomised, crossover trial with interferon alfa-2b. A significant improvement was seen in the purpura score and alanine aminotransferase activities during six months9 treatment, and was associated with a significant decrease in cryocrit and a returning to normal of the lymphocyte CD4/CD8 ratio (in eight of nine patients). No significant variations were seen during the six month period without interferon. Only six patients withdrew from treatment, three because of side effects and three because of poor compliance.